Data Highlights the Potential of the CUE-100 Series to Selectively Deliver IL-2 to Tumor-relevant T cells while Mitigating the Risk Associated with Systemic IL-2 Activation CAMBRIDGE, Mass. , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy company
WT1 is a Well-Characterized Oncofetal Antigen, Expressed in Solid Tumors and Hematologic Malignancies CAMBRIDGE, Mass. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma ™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to
CAMBRIDGE, Mass. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases,
CUE-101 Demonstrates Selective Binding and Preferential Activation/Expansion of Antigen-specific T Cells, Inhibition of Tumor Growth as Monotherapy and in Combination with a PD-1 Inhibitor CAMBRIDGE, Mass. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma ™, Inc., (NASDAQ: CUE) an innovative
Collaboration Expands Development and Manufacturing of Immuno-STAT™ Biologics and Broadens Coverage of Patient Populations CAMBRIDGE, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma ™, Inc. (NASDAQ: CUE), an innovative immunotherapy company developing a novel, proprietary class of
CAMBRIDGE, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma ™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases,
Overview and Update on the ImmunoSTAT™ Platform for Selective Targeting of Disease-Relevant T cells CAMBRIDGE, Mass. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma ™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to
CAMBRIDGE, Mass. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases,
Update on progress of selective immune modulation platform CAMBRIDGE, Mass. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to